Please use this identifier to cite or link to this item:
|Title:||A subset of flavaglines inhibits KRAS nanoclustering and activation||Authors:||Yurugi, Hajime
Siddiqui, Farid A.
|Keywords:||Engineering::Bioengineering||Issue Date:||2020||Source:||Yurugi, H., Zhuang, Y., Siddiqui, F. A., Liang, H., Rosigkeit, S., Zeng, Y., Abou-Hamdan, H., Bockamp, E., Zhou, Y., Abankwa, D., Zhao, W., Désaubry, L. & Rajalingam, K. (2020). A subset of flavaglines inhibits KRAS nanoclustering and activation. Journal of Cell Science, 133(12). https://dx.doi.org/10.1242/jcs.244111||Project:||M4082114
|Journal:||Journal of Cell Science||Abstract:||The RAS oncogenes are frequently mutated in human cancers and among the three isoforms (KRAS, HRAS and NRAS), KRAS is the most frequently mutated oncogene. Here, we demonstrate that a subset of flavaglines, a class of natural anti-tumour drugs and chemical ligands of prohibitins, inhibit RAS GTP loading and oncogene activation in cells at nanomolar concentrations. Treatment with rocaglamide, the first discovered flavagline, inhibited the nanoclustering of KRAS, but not HRAS and NRAS, at specific phospholipid-enriched plasma membrane domains. We further demonstrate that plasma membrane-associated prohibitins directly interact with KRAS, phosphatidylserine and phosphatidic acid, and these interactions are disrupted by rocaglamide but not by the structurally related flavagline FL1. Depletion of prohibitin-1 phenocopied the rocaglamide-mediated effects on KRAS activation and stability. We also demonstrate that flavaglines inhibit the oncogenic growth of KRAS-mutated cells and that treatment with rocaglamide reduces non-small-cell lung carcinoma (NSCLC) tumour nodules in autochthonous KRAS-driven mouse models without severe side effects. Our data suggest that it will be promising to further develop flavagline derivatives as specific KRAS inhibitors for clinical applications.||URI:||https://hdl.handle.net/10356/149025||ISSN:||0021-9533||DOI:||10.1242/jcs.244111||Rights:||© 2020 The Author(s). All rights reserved. This paper was published by The Company of Biologists Ltd in Journal of Cell Science and is made available with permission of The Author(s).||Fulltext Permission:||open||Fulltext Availability:||With Fulltext|
|Appears in Collections:||SCBE Journal Articles|
Updated on Aug 27, 2021
Updated on Aug 24, 2021
Updated on May 26, 2022
Updated on May 26, 2022
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.